Verastem Oncology Announces Global Licensing Agreement With Chugai Pharmaceutical Co., Ltd. To Develop And Commercialize RAF/MEK Inhibitor CH5126766; Co. To Make $3M Upfront Payment To Chugai And Pay Royalties